JAKARTA - Aidence, a software company in medical diagnostics using AI has announced an agreement to license Google Health's AI research model for predictions of the ferocity of pulmonary nodules in CT imaging.
In this agreement, Aidence will develop, validate, and bring this model to the market to support early diagnosis and accurate lung cancer as well as unnecessary reduction of procedures in screening programs.
The 2020 NELSON trial revealed that low-dose lung cancer screening has been shown to significantly reduce lung cancer deaths by up to 24 percent for men and 33 percent for women.
Engaging the right partners can help unlock impact at scale.We're proud to announce a partnership with @AidenceVeye to license our lung #AI research model, with the goal of identifying high risk patients sooner. Learn more: https://t.co/aR0lIV08Ic pic.twitter.com/emeEppSGzu
— Google Health (@GoogleHealth) November 28, 2022
However, there are major difficulties in screening lung cancer, namely determining the nature of the pulmonary nodules detected. Most of these nodules are not cancerous. Identifying and diagnosing nodules correctly can take a lot of time at an expensive cost.
Dr Raymond Osarogiagbon, Chief Scientist,▁sikapt Memorial Health Care Company and Director, Multidisciplinary Toraks Oncology Program, Obligatory Cancer Center, Memphis, Tennessee, explains that artificial intelligence is one solution.
Deep learning, part of AI, has proven to support the risk assessment of the ferocity of pulmonary nodules. In a study published in Nature in 2019, scientists affiliated with Google Health presented a very accurate model for the classification of ferocity.
On the other hand, Aidence is also building an in-depth learning model for this purpose. Algorithm Aidence has successfully predicted lung cancer from one scan and was awarded the challenge of the 2017 Kaggle.
With Aidence and Google Health collaborations, the two companies intend to complement AI applications to predict the ferocity of pulmonary nodules. Google Health will provide its scientific expertise while Aidence will develop the model into a solution for clinical practice and bring it to market.
Our mission at Aisidence is to give lung cancer patients the opportunity to fight. This strategic partnership with Google Health allows us to accelerate and expand our efforts to achieve it," said Mark-Jan Harte, co-founder and CEO of Aidence in an announcement shared on Twitter.
Akib Uddin, Product Manager at Google Health, added: At Google Health, we want to be an active catalytic force in demonstrating the real-world benefits of AI in health. We know how important lung cancer screening is in saving lives, and we are pleased to play a role in driving impact on a large scale by enabling great partners like Aidence with our technology."
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
